VALENCIA, Calif., Sept. 14 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD - News) today announced the completion of patient enrollment in the pivotal long-term safety study of Technosphere® Insulin, an investigational inhaled insulin formulation delivered via the Company's proprietary inhaler to patients with diabetes mellitus. Over 1,800 subjects have been enrolled in this open-label, randomized, prospective study, which will evaluate the pulmonary safety of Technosphere® Insulin in patients with type 1 and type 2 diabetes as well as a subgroup of individuals without diabetes. This study is the first pivotal study to complete enrollment and is part of a comprehensive Phase 3 clinical program for which the additional pivotal studies, of shorter duration, are now all actively recruiting at centers in the United States, Europe and Latin America.
